论文部分内容阅读
目的：评价帕洛诺司琼在预防晚期肺癌恶性胸腔积液胸腔化疗所致恶心止吐的疗效并与托烷司琼对比。方法46例晚期肺癌伴恶性胸腔积液需行顺铂胸腔化疗的患者随机分为实验组（帕洛诺司琼组，n=23）和对照组（托烷司琼组， n=23），观察并比较两组病人预防恶心止吐的效果及不良反应。结果实验组和对照组的急性恶心有效控制率分别为87.0%和78.3%，急性呕吐有效控制率分别为73.9%和60.9%，两组相比无显著性差异（P＞0.05）；在迟发性恶心和呕吐有效控制率方面，帕洛诺司琼组分别为78.3%和69.6%，托烷司琼组分别为47.8%和34.8%，两者具有显著性差异（P＜0.05）。治疗期间有部分患者出现腹胀、便秘及头晕，两组相比无显著性差异（P＞0.05）。结论帕洛诺司琼与托烷司琼在预防晚期肺癌恶性胸腔积液患者行顺铂胸腔化疗所致急性恶心呕吐的疗效相当，但对于迟发性恶心呕吐帕洛诺司琼有更好的效果。“,”Objective To compare the efficacy of Palonosetron with Tropisetron in prevention of nausea and vomiting induced by thoracic chemotherapy with cisplatin in advanced lung cancer patients with malignant pleural effussion.Methods 46 advanced lung cancer patients with malignant pleural effussion were enrolled and divided into two groups(Palonosetron group and Tropisetron group) randomly.In the P group,Palonosetron was administered before thoracic chemotherapy with cisplatin;in the T group,Tropisetron was administered before thoracic chemotherapy with cisplatin.The incidence rates of nausea,vomiting were evaluated and the side effects were calculated by WHO standard.Result There were not statistically signiifcant difference in the incidence rates of acute nausea and vomiting between the P group and the T group.But in the incidence rates of delayed nausea and vomiting between the P group and the T group,there were statistically signiifcant differences.And there were no statistically significant difference in the adverse effects.Conclusion Palonosetron has the same effects as Tropisetron in the prevention of acute nausea and vomiting induced by thoracic chemotherapy with cisplatin,but it has better effects in the prevention of delayed nausea and vomiting induced by thoracic chemotherapy with cisplatin.